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Available online xxxxGaucher disease is an inherited metabolic disease characterized by β-glucocerebrosidase deﬁciency and com-
monly treatedwith enzyme replacement therapy (ERT). The efﬁcacy of ERTwith velaglucerase alfa was assessed
based on the achievement of published therapeutic goals and the normalization of disease parameters in 39
treatment-naïve patients with type 1 Gaucher disease, 6 to 62 years of age, enrolled in phase 3 clinical trials.
After 4 years of ERT, therapeutic goals for thrombocytopenia and splenomegaly had been achieved in 100% of pa-
tients; goals for anemia and hepatomegaly had been achieved in 95% and 94% of patients, respectively. Consistent
with the goal for bone mineral density, lumbar spine bone density improved in 87% of patients ≥18 years of age.
At year 4, compared with clinical ranges for healthy individuals, 86% of patients with a low baseline hemoglobin
concentration had normalized, 60%with a low baseline platelet count had normalized, 67%with baseline spleno-
megaly had normalized, 58%with hepatomegaly had normalized, and lumbar spine bone density had normalized
in 53% of adults. The decade-old therapeutic goals do not reﬂect the potential for normalization of clinical param-
eters in ERT-treated patients. Goals consistent with normalization or near-normalization should be considered.
ClinicalTrials.gov identiﬁers: NCT00430625, NCT00553631, NCT00635427.
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Velaglucerase alfa1. Introduction
Type 1 Gaucher disease (GD) is a rare inherited metabolic disease
that leads to thrombocytopenia, anemia, hepatosplenomegaly, delayed
growth in children, and various skeletal abnormalities. The severity of
the disease and the age at which symptoms start differs considerably
between patients [1].
Long-term enzyme replacement therapy (ERT) is indicated in symp-
tomatic patients to replace the lysosomal enzyme that is deﬁcient in GD.
Of three currently available exogenous enzymes for ERT, imiglucerase,
velaglucerase alfa, and taliglucerase alfa, velaglucerase alfa is the onlyyme replacement therapy; GD,
k Medical Center, 1 Bazak Road,
lstein-c@shire.com (D. Elstein),
gmail.com (E.A. Lukina),
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ood Cells Mol. Diseases (2016one that is produced by gene activation in a human cell line and results
in a protein with the identical amino acid sequence as the naturally oc-
curring human enzyme [2]. The two other enzymes are produced in a
Chinese hamster ovary mammalian or plant-based expression system
and have primary structures that differ from the natural human enzyme
by one amino acid residue (imiglucerase) or 10 amino acid residues
(taliglucerase alfa) [3–5]. The glycosylation patterns between these
three enzymes also are different [6]. It is unclear whether these product
differences affect their relative efﬁcacy and safety proﬁles.
Long-term ERT is expected to lead to improvements in the signs and
symptoms of type 1 GD. Pastores and colleagues deﬁned a number of
therapeutic goals for the treatment of GD, which were published over
10 years ago and were based on data from the medical literature and
the collective clinical experience of an international panel of physicians
[7]. The goals took into account common observations in treated pa-
tients, including the realization that in patientswithGD, anemia and he-
patomegaly were more multifactorial than thrombocytopenia and
splenomegaly. It was appreciated that severely enlarged spleens were
unlikely to be completely corrected to volumes seen in healthy individ-
uals, and also that the severity of thrombocytopenia before treatment
helped predict the extent to which the platelet count improved [8].), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
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ed in eight adult patients treated with velaglucerase alfa in a
phase 1/2 study; ﬁve long-term goals were met in all eight pa-
tients by 4 years of velaglucerase alfa treatment [9]. Furthermore,
normal or near-normal clinical values were achieved in this adult
cohort [10].
In a subsequent long-term phase 3 extension study of velaglucerase
alfa ERT (study name, HGT-GCB-044), the efﬁcacy of velaglucerase
alfa was evaluated using therapeutic goals. A total of 93 patients
with type 1 GD from three separate clinical trials were enrolled in
the extension study, which included both pediatric and adult pa-
tients. The therapeutic goals analysis was a post hoc efﬁcacy analysis
to determine whether or not goals of GD treatment were achieved
within speciﬁc time periods after the initiation of treatment. The pri-
mary efﬁcacy analysis [11] showed signiﬁcant continued improve-
ments in patients who were treatment naïve before their ﬁrst
velaglucerase alfa dose and who received 2.3 to 5.8 years of
velaglucerase alfa treatment. We present the therapeutic goals anal-
ysis conducted in this study population and a further post hoc anal-
ysis designed to explore how much more was achieved clinically,
beyond the therapeutic goals and toward normal-range values, in
patients receiving velaglucerase alfa.2. Methods
2.1. Extension study HGT-GCB-044
HGT-GCB-044 was a multicenter, open-label, phase 3 extension
study (ClinicalTrials.gov identiﬁer NCT00635427) into which patients
from three separate clinical trials were enrolled. Only patients who
were treatment naïve upon enrolling in the seminal trials were included
in this analysis; these were patients from two phase 3, double-blind,
randomized controlled trials [12,13]. All studies received institutional
review board or independent ethics committee approval at the sites
where theywere conducted and followed local regulations and Interna-
tional Conference on Harmonisation Good Clinical Practice guidelines,
including obtaining written informed consent for each patient.
The two randomized controlled studies have been described in detail
elsewhere (ClinicalTrials.gov identiﬁers NCT00430625, NCT00553631)
[12,13]. Brieﬂy, treatment-naïve patients with type 1 GD over 2 years of
age and with clinical signs of GD were enrolled and randomized to one
of two treatment groups: velaglucerase alfa 60 U/kg and either imigluce-
rase 60 U/kg in a 9-month noninferiority trial [12], or velaglucerase alfa
45 U/kg in a 12-month two-dose trial [13]. All patients had a 60-min
ERT intravenous infusion every other week regardless of the drug or
dose to which they were randomized.
Patients who completed one of the seminal trials could enroll in the
extension study in which all patients received velaglucerase alfa at a
dose of 60 U/kg (at least in the ﬁrst year, after which dose reduction
was allowed) and they could continue participating in the extension
study until commercial velaglucerase alfa was available to them [11].
Efﬁcacy assessments in both the extension and seminal studies in-
cluded blood sampling for hemoglobin concentration and platelet
counts every 2 or 12 weeks; abdominal magnetic resonance imaging
for visceromegaly assessment at baseline, 6months, 9months (noninfe-
riority trial only), 12 months, and every year thereafter; dual-energy X-
ray absorptiometry of the proximal femurs and the lumbar spine every
year in patients ≥18 years of age to measure bone mineral density
(BMD); and heightmeasurements approximately every 3months in pa-
tients b18 years of age.
Organ volumes were expressed as a percentage of body weight and
as multiples of normal (MN), where 0.2% body weight is 1 MN for the
spleen and 2.5% bodyweight is 1MN for the liver. BMD and heightmea-
surements were converted to age- and sex-matched Z-scores, and
height percentiles also were calculated as previously described [11,14].Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (20163. Analysis
The data were analyzed by Shire's Biostatistics and Statistical Pro-
gramming department and all authors had access to the primary clinical
trial data.
Only patients who received velaglucerase alfa in both the seminal
and extension studies were included in this analysis; therefore, we ana-
lyzed a group who received velaglucerase alfa throughout and did not
switch from imiglucerase.
The treatment response was evaluated against the therapeutic goals
for hemoglobin concentration, platelet count, spleen and liver volumes,
BMD, and height for age (Table 1). We assessed the achievement of
therapeutic goals at baseline and at yearly intervals after the initiation
of ERT. Results presented here are after 1 year of ERT (or 3 years for
BMD and height) and after 4 years of ERT.
We used shift tables to show the numbers of patients meeting the
therapeutic goal at a particular time point in the patients in whom the
goal was already met at baseline and patients whose clinical values at
baselinewere outside the therapeutic goal range. Analogous shift tables
were drawn to show the numbers of patients whose clinical values fell
within a healthy (normal reference) range (Table 2) at the same time
points. Severely enlarged spleens appear to have a limited capacity to
reduce in volume and in previous publications, 5MNhas been identiﬁed
as the upper limit ofmild splenomegaly [7,8,15], so spleen volumes that
fell to ≤5 MN were considered to have normalized. We used−1 as the
cutoff for normal BMD Z-scores, whichmeant that Z-scores no N1 stan-
dard deviation below the age- and sex-matched reference population
meanwere considered to bewithin normal limits (similar to the catego-
rization of BMDT-scores of at least−1 as normal [16]). Analyses of liver
volume were repeated after excluding splenectomized patients, be-
cause hepatomegaly is generally greater in splenectomized patients.
We did not perform data imputation for missing values, so in a few in-
stances where baseline data were missing, those patients were exclud-
ed from the analysis of that variable.
To show the extent of improvement achieved by year 4 in each indi-
vidual patient, we also plotted individual patients' clinical values at
baseline and at 4 years on the same graph.
4. Results
Ninety-three patients with type 1 GD received the study drug
velaglucerase alfa in the extension study. Thirty-nine of these patients
were treatment naïve before receiving their ﬁrst dose of velaglucerase
alfa in the preceding trial. All 39 patients were included in this analysis
(Table 3): eight pediatric patients 6 to 16 years of age, and 31 adults 18
to 62 years of age.
Twelve patients had a baseline platelet count b60×109/L and four of
eight pediatric patients were below the ﬁfth height percentile. The du-
ration of velaglucerase alfa exposure from baseline to the end of the ex-
tension study in the analysis group ranged between 2.3 and 5.8 years
(mean dose, 56.6 U/kg). Thirty of 39 patients received ≥4 years of treat-
ment with the study drug, but most patients had completed or
discontinued from the extension study by 5 years, including patients
who stopped participating in the study once commercial velaglucerase
alfa became available [11].
4.1. Hematology and organ volumes after 1 year of ERT
4.1.1. Therapeutic goals
Short-term therapeutic goals (within 1–2 years; Table 1) for hemo-
globin concentration, platelet count, and spleen and liver volume were
achieved in patients receiving velaglucerase alfa (Table 4). The goal for
hemoglobin was achieved in 23 of 24 (96%) patients who had a hemo-
globin level below the therapeutic goal for age and sex at baseline,
and the short-term goal for platelet count was achieved in 15 of 25
(60%) patients who had a platelet count b120 × 109/L at baseline), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
Table 1
Goals for Gaucher disease treatment according to time from initiation of enzyme replacement therapy.
Characteristic At 1 year At 2–5 years At baselinea
Hemoglobin Female or ≤12 years of age ≥11 g/dL Same as 1 year ≥11 g/dL
Male and N12 years of age ≥12 g/dL Same as 1 year ≥12 g/dL
Platelet count Nonsplenectomized ≥50% increase
(or ≥120 × 109/L)
2 years and after:
≥100% increase if baseline was b60 × 109/L
≥100 × 109/L if baseline was ≥60 and b120 × 109/L
≥120 × 109/L if baseline was ≥120 × 109/L
≥120 × 109/L
Splenectomized ≥120 × 109/L Same as 1 year ≥120 × 109/L
Spleen volume Nonsplenectomized ≥30% decrease
(or ≤8.0 MN)
2 years and after: ≥50% decrease compared with baseline (or ≤8.0 MN) ≤8.0 MN
Liver volume All patients ≥20% decrease
(or ≤1.5 MN)
3 years and after: ≥30% decrease compared with baseline (or ≤1.5 MN) ≤1.5 MN
BMD ≥18 years of age n/a 3 years and after: Z-score change N0 n/a
Linear growth b18 years of age n/a 3 years and after: above ﬁfth height percentile Above ﬁfth height percentile
BMD, bone mineral density; MN, multiples of normal; n/a, not applicable.
The criteria shown here are consistent with the therapeutic goals deﬁned by Pastores and colleagues [7].
a Values considered to be within therapeutic goal range before treatment.
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volumes were met in 22 of 23 (96%) patients with spleen volumes N8
MN (whichwould be the cutoff as per the therapeutic goals) at baseline
and 14 of 18 (78%) patients with liver volumes N1.5 MN at baseline.4.1.2. Normalization
When we analyzed the group at baseline and at 1 year post baseline
using clinical ranges for healthy individuals (Table 2), we observed a
low baseline hemoglobin level in 33 patients (of 36 patients with data
at both time points) even though only 24 patients were considered to
be below the therapeutic goal. We observed a low platelet count in 25
of 34 patients, splenomegaly in 27 of 28 nonsplenectomized patients,
and hepatomegaly in 33 of 35 patients (Table 5).
At 1 year, normalization of hemoglobin concentration was observed
in the vastmajority of patients whohad a low hemoglobin level at base-
line (27 of 33; 82%). As early as year 1, platelet counts normalized in 9 of
25 (36%) patients who had a low baseline platelet count. At 1 year,
spleen volume normalized in 9 of 27 (33%) patients with baseline
splenomegaly and liver volume normalized in 11 of 33 (33%) patients
who had hepatomegaly. After excluding splenectomized patients, 8 of
26 (31%) patients who had hepatomegaly were found to have
normalized.Table 2
Clinical criteria considered to represent normalization.
Criteria
Hemoglobin concentration
6–12 years of age 11.2–15.5 g/dL
12–59 years of age
Female 11.6–16.4 g/dL
Male 12.7–18.1 g/dL
≥59 years of age
Female 11.5–15.8 g/dL
Male 12.5–17.0 g/dL
Platelet count
6–12 or ≥60 years of age 130–394 × 109/L
12–60 years of age 140–400 × 109/L
Spleen volume ≤5.0 MN
Liver volume ≤1.0 MN
BMD Z-score ≥ −1.0
BMD, bone mineral density; MN, multiples of normal.
Hemoglobin and platelet reference ranges were from the central laborato-
ry (Covance Central Laboratory Services, Indianapolis, IN, and Geneva,
Switzerland).
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (20164.2. Hematology and organ volumes after 4 years of ERT
4.2.1. Therapeutic goals
Of the patients who had clinical values outside the therapeutic goal
range at baseline, the goal for hemoglobin concentration was achieved
in 19 of 20 (95%) patients, the long-term goal for platelet count was
achieved in all 20 (100%) patients, and the goals for spleen and liver vol-
ume were achieved in all 16 (100%) patients and in 15 of 16 patients
(94%), respectively (Table 4). One patient's liver volume and another
patient's hemoglobin concentration at 4 years did not meet the long-
term therapeutic goals, although the goals were met at the subsequent
volumetric assessment and hematology test.4.2.2. Normalization
Normalization of hemoglobin concentration was observed in 24 of
28 (86%) patients who had a low hemoglobin level at baseline; platelet
count normalized in 12 of 20 patients (60%). At year 4, 12 of 18 (67%)
patients with baseline splenomegaly experienced normalization and
15 of 26 (58%) patients with hepatomegaly experienced normalization
(or 11 of 19 [also 58%] patients, after excluding splenectomized
patients).4.3. BMD in adults: therapeutic goal and normalization
Consistent with the therapeutic goal for BMD in adults [7], the lum-
bar spine BMD Z-score was increased compared with baseline in 26 of
27 (96%) patients at year 3 and 20 of 23 (87%) patients at year 4. The
femoral neck BMD Z-score was increased in 20 of 28 (71%) patients at
year 3 and 16 of 23 (70%) patients at year 4. The Z-score change ob-
served varied between patients (Fig. 1), but on average, there was a
mean 66% increase in lumbar spine BMD Z-scores from baseline to
4 years and an 11% increase in femoral neck Z-scores.
At year 4, lumbar spine BMD had normalized (from Z-score below
−1 to Z-score of at least−1) in 10 of 19 (53%) patients; normalization
was not observed in the femoral neck in any of the 6 patients who had a
low baseline femoral neck Z-score.4.4. Patients with normal values at 4 years
At 4 years, normalization of hemoglobin concentration, platelet
count, spleen volume, liver volume, and lumbar spine BMD (abnormal
to normal value) had been observed in 80%, 41%, 63%, 56%, and 43%, re-
spectively, of all patientswith data,while 7%, 28%, 5%, 4%, and 13% of pa-
tients had remained normal (normal both at baseline and after
treatment) for the same variables (Table 6).), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
Table 3
Patient characteristics at baseline or 4 years (N= 39).
Characteristic Baseline 4 years
Patients with data Median (range) or no. (%) Patients with data Median (range)
Age, years 39 29 (6, 62)
b18 years of age, no. (%) 39 8 (21)
Male, no. (%) 39 21 (54)
Splenectomized patients, no. (%) 39 9 (23)
Hemoglobin, g/dL 39 10.9 (7.1, 14.4) 30 14.1 (10.4, 17.3)
Platelet count, ×109/L 38 82.5 (13, 310) 29 170 (108, 439)
Spleen volume, MN 29 13.6 (4.8, 65.1) 19 4.2 (1.8, 15.0)
Liver volume, MN 38 1.5 (0.8, 3.2) 27 1.0 (0.7, 1.6)
Lumbar spine BMD,a Z-score 31 –1.73 (−4.20, 0.78) 23 –0.74 (−2.90, 2.33)
Femoral neck BMD,a Z-score 31 –0.59 (−2.77, 2.37) 23 –0.54 (−2.37, 3.12)
Height for age,b Z-score 8 –1.54 (−2.70,−0.37) 5 –0.57 (−1.77, 0.12)
BMD, bone mineral density; MN, multiples of normal.
a Patients ≥18 years of age.
b Patients b18 years of age.
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World Health Organization growth reference data were used in this
study, which are available for children and adolescents ≤19.0 years of
age. Seven of eight pediatric patients were b19 years of age (between
9.2 and17.3 years) after 3 years of studyparticipation. All seven patients
were above the ﬁfth height percentile at 3 years and thus met the ther-
apeutic goal for linear growth, including three patients whowere below
the ﬁfth height percentile at baseline. Baseline height percentiles were
0.9, 2.0, 4.0, 9.2, 12.9, 14.0, and 35.6, and year 3 percentiles were 8.1,
26.4, 14.7, 12.7, 29.5, 56.4, and 59.5, respectively.
The eighth patientwas 16.8 years of age at baselinewith a height per-
centile of 0.3; at 17.8 years of age (month 12), his height percentile was
3.1 and at 18.9 years of age (month 27), it had improved further to 5.7.
Five pediatric patients had height-for-age data at 4 years (Table 3),
four of whom remained above the ﬁfth height percentile. One 7-year-
old patient who improved from a height percentile of 0.9 at baseline
to the eighth percentile by 3 years was subsequently at percentile
3.8 at 4 years, although this was still an improvement from baseline.5. Discussion
The therapeutic goals of GD treatment are meant to indicate what
can reasonably be anticipated in the ﬁrst few years of ERT; for ﬁveTable 4
Number of patients who met the therapeutic goals at baseline and after treatment.
Goal met at baseline, no. Goal met at 1 y
(3 y for BMD),
no.
Goal met at 4 y,
no.
Yes No Yes No
Hemoglobin
Baseline yes 12 0 10 0
Baseline no 23 1 19 1
Platelet count
Baseline yes 9 0 9 0
Baseline no 15 10 20 0
Spleen volume
Baseline yes 5 0 3 0
Baseline no 22 1 16 0
Liver volume
Baseline yes 17 0 11 0
Baseline no 14 4 15 1
Lumbar spine BMD
Baseline no 26 1 20 3
Femoral neck BMD
Baseline no 20 8 16 7
BMD, bone mineral density.
The BMD goal (a Z-score improvement compared with baseline) was not applicable at
baseline, so no patients met the BMD goal at baseline.
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016clinical variables, our study suggests that normalization or near-
normalization is not an unreasonable expectation and the goals should
change to reﬂect this.
The therapeutic goals for four hematological and visceral variables
and BMDwere achieved by year 4 or maintained in 100% (n= 8) of pa-
tients receiving velaglucerase alfa in a phase 1/2 studywherein normal-
ization of clinical variables also was observed [9,10]. In the present
study, 60% to 96% of patients achieved short-term therapeutic goals
for the same four hematological and visceral variables in the ﬁrst year
of ERT, and 94% to 100% achieved the individual long-term goals for
the same variables at 4 years. At the same time, therapeutic goals
were maintained in 100% of the patients in whom the goals were con-
sidered already met at baseline (overall, 96–100% of all patients at
4 years had clinical measurements that met the individual hematologi-
cal and visceral goals). We also observed the achievement of the BMD
goal in the lumbar spine in 87% of adults. Therefore, the results of our
therapeutic goal analyses support those from the phase 1/2 study. We
also can add a further observation that height for age improved in pedi-
atric patients receiving velaglucerase alfa who had a median height Z-
score of−1.54 at baseline.
In a retrospective study of patients who enrolled in a disease
registry, 92%, 80%, 79%, and 91% of patients met the goals for hemoglo-
bin concentration, platelet count, spleen volume, and liver volume,Table 5
Number of patients who had normal clinical values at baseline and after treatment.
Normal at baseline, no. Normal at 1 y
(3 y for BMD), no.
Normal at 4 y,
no.
Yes No Yes No
Hemoglobin
Baseline yes 3 0 2 0
Baseline no 27 6 24 4
Platelet count
Baseline yes 8 1a 8 1a
Baseline no 9 16 12 8
Spleen volume
Baseline yes 1 0 1 0
Baseline no 9 18 12 6
Liver volume
Baseline yes 1 1 1 0
Baseline no 11 22 15 11
Lumbar spine BMD
Baseline yes 4 0 3 1
Baseline no 9 14 10 9
Femoral neck BMD
Baseline yes 20 1 15 2
Baseline no 0 7 0 6
BMD, bone mineral density.
a Normal platelet count at baseline and a higher-than-normal platelet count after
treatment.
), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
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Fig. 1. Achievement of therapeutic goals and/or normal clinical values in individual patients. Panels show data for (A) hemoglobin concentration, (B) platelet count, (C) spleen volume,
(D) liver volume, (E) lumbar spine BMD, and (F) femoral neck BMD. Each vertical line plotted represents a single patient; crosses indicate the baseline values and dots indicate the
values after 4 years of velaglucerase alfa enzyme replacement therapy. Long-term therapeutic goals are deﬁned in Table 1 and are shown as dashed horizontal lines in panels A–D.
Normal clinical values are deﬁned in Table 2 and are shown as solid horizontal lines in panels B–F. BMD, bone mineral density; MN, multiples of normal.
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spectively, 100%, 47%, 100%, and 94% of patients met the goals for the
same variables after 4 years of treatment with eliglustat, which is not
an ERT but an oral substrate reduction therapy, in a phase 2 study
(N = 19) [18]. In a single-center study by Tukan and colleagues, 53% toTable 6
Proportion of whole study group who normalized after 4 years of ERT by clinical parameter.
Hemoglobin Platelets Sp
Total patient number 30 29 19
Abnormal → normal (normalized) 24 (80%) 12 (41%) 12
Normal → normal (remained normal) 2 (7%) 8 (28%) 1
Abnormal → abnormal (remained abnormal) 4 (13%) 8 (28%) 6
Normal → abnormal 0 1 (3%) 0
BMD, bone mineral density.
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (201682%of patientsmet these goals by 4 years of low-dose imiglucerase treat-
ment (N=164) and100% of a pediatric subgroupwhowere b14 years of
age at baseline achieved the goal for height in the same period [19].
The results of the above studies may not be comparable with the
present study. For example, the study design and completeness ofleen volume Liver volume Lumbar spine BMD Femoral neck BMD
27 23 23
(63%) 15 (56%) 10 (43%) 0
(5%) 1 (4%) 3 (13%) 15 (65%)
(32%) 11 (41%) 9 (39%) 6 (26%)
0 1 (4%) 2 (9%)
), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
6 A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxdata collection in a disease registry are generally very different from
clinical trials. Also, unlike the present study, splenectomized patients
were excluded from both the eliglustat and registry studies, and a
wide or lower range of unit/kg ERT doses were used in the imiglucerase
studies. However, these previous studies suggest that a signiﬁcant num-
ber of patients can have an incomplete treatment response, or improve-
ment in some clinical variables but not others.
Although we did not expect the same proportion of patients who
met the therapeutic goals to experience normalization, normalization
was observed in up to 86% of patients for the ﬁve disease parameters
evaluated. This follows two previous reports in which patients with
type 1 GD treated with ERT experienced normalization of disease vari-
ables, particularly hemoglobin concentration and liver volume [10,15],
and other reports showing a substantial treatment response that tended
to normalization [20]. The production of velaglucerase alfa in a human
cell line, as a product with the native human amino acid sequence,
may have contributed to the results observed in this cohort; further re-
search is needed to explore this further.
In this study, patients considered to have met a therapeutic goal at
baseline, or after ERT, did not necessarily have normal clinical values,
so there was potentially room for further improvement. In the case of
spleen volume, volume reduction is sometimes limited by the presence
of splenic lesions [21]. Nevertheless, our results suggest that normaliza-
tion of important disease parameters is generally likely to be achieved;
at least, values that are closer to normal can reasonably be considered
the goals of GD treatment. The current therapeutic goals were based
on results that were seen mostly in patients exposed to one particular
GD-speciﬁc therapy over well-deﬁned but arbitrary time frames of 1
to 2, 3, or 5 years. Considering the current evidence, perhaps we should
expect normalization or near-normalization of values inmost cases, and
also for some patients who are “slow responders” to continue to im-
prove gradually after the arbitrary cutoff points of 1 year, 2 years, and
so on.
5.1. Limitations of analysis
Clinical reference ranges are not without controversy, because clini-
cal values that are slightly outside normal ranges can sometimes still
meet a person's physiologic needs. The beneﬁts of achieving speciﬁc
therapeutic goals on a patient's long-term clinical outcomes have not
been demonstrated, and if patients achieve more than the currently
established therapeutic goals, we cannot yet link this directly to better
outcomes, quality of life, or patient satisfaction, although anemia and
low lumbar spine BMD may be risk factors for skeletal complications
of GD (avascular necrosis and fractures) [22]. Above 1500 to 2000 mL,
spleen volumes may not make a signiﬁcant difference to the function
of the spleen [23,24] (we calculated that 100% of patients in our study
had spleen volumes below 2000mL at year 4). Further research, includ-
ing outcomes research (most feasibly done via disease registries), even
assessing surrogate outcomes, is needed.
Composite analyses including multiple disease variables may be re-
quired to best assess the effect of ERT onGD [25], rather than analyses of
individual variables as presented here.
Finally, this analysis was limited by the attrition in patient numbers
over time because of the availability of and switching to commercial
velaglucerase alfa, meaning that there was missing follow-up data for
some patients; however, 30 of 39 (77%) patients were still participating
in the study at 4 years.
6. Conclusions
The therapeutic goals for GD treatment that are now over a decade
old do not reﬂect the potential for normalization of clinical parameters
in ERT-treated patients. Our results suggest that goals consistent with
normalization or near-normalization should be considered instead.Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016Authorship contributions
AZ, DE, DEG, EAL, and HBwere investigators in the clinical trials. AZ,
DE, andQDcontributed to the analysis plan and interpreted data. YQ an-
alyzed and checked the data. All authors revised the manuscript and
gave ﬁnal approval of the manuscript.
Conﬂict of interest disclosures
Research supported by company (AZ: Shire). Current or recent par-
ticipation in a clinical trial sponsored by company (AZ: Shire). Honoraria
(AZ: Genzyme, Pﬁzer, Shire). Employed as contractor for Shire (DE).
Consulting fees (EAL: Genzyme, Shire). Membership on advisory
board or committee (EAL: Genzyme, Shire). Contracted research (EAL:
Genzyme, Shire;HB: Shire). Employee of Shire (YQ,QD). DEG has nopo-
tential competing interests to declare.
Acknowledgments
Research was funded by the sponsor, Shire International GmbH.
Under the direction of the authors, Clare Guni, BMBS, employee of
Excel Scientiﬁc Solutions, provided writing assistance for this publica-
tion. Editorial assistance in formatting, proofreading, copyediting, and
fact checking also was provided by Excel Scientiﬁc Solutions. Shire In-
ternational GmbHprovided funding to Excel Scientiﬁc Solutions for sup-
port in writing and editing this manuscript.
References
[1] A. Zimran, D. Elstein, Gaucher disease and related lysosomal storage diseases, in: K.
Kaushansky, M.A. Lichtman, J.T. Prchal, M.M. Levi, O.W. Press, L.J. Burns, M. Caligiuri
(Eds.), Williams Hematology, McGraw-Hill, New York 2015, pp. 1121–1131.
[2] A. Zimran, K. Loveday, C. Fratazzi, D. Elstein, A pharmacokinetic analysis of a novel
enzyme replacement therapy with gene-activated® human glucocerebrosidase
(GA-GCB) in patients with type 1 Gaucher disease, Blood Cells Mol. Dis. 39 (2007)
115–118.
[3] Genzyme Corporation, Cerezyme® (imiglucerase for injection). Proposed labeling of
the drug, 2003. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/
20367s066lbl.pdf accessed.
[4] Y. Shaaltiel, D. Bartfeld, S. Hashmueli, G. Baum, E. Brill-Almon, G. Galili, O. Dym, S.A.
Boldin-Adamsky, I. Silman, J.L. Sussman, A.H. Futerman, D. Aviezer, Production of
glucocerebrosidase with terminal mannose glycans for enzyme replacement thera-
py of Gaucher's disease using a plant cell system, Plant Biotechnol. J. 5 (2007)
579–590.
[5] B. Brumshtein, P. Salinas, B. Peterson, V. Chan, I. Silman, J.L. Sussman, P.J. Savickas,
G.S. Robinson, A.H. Futerman, Characterization of gene-activated human acid-β-
glucosidase: crystal structure, glycan composition, and internalization into macro-
phages, Glycobiology 20 (2010) 24–32.
[6] Y. Tekoah, S. Tzaban, T. Kizhner, M. Hainrichson, A. Gantman, M. Golembo, D.
Aviezer, Y. Shaaltiel, Glycosylation and functionality of recombinant β-
glucocerebrosidase from various production systems, Biosci. Rep. 33 (2013),
e00071.
[7] G.M. Pastores, N.J. Weinreb, H. Aerts, G. Andria, T.M. Cox, M. Giralt, G.A. Grabowski,
P.K. Mistry, A. Tylki-Szymańska, Therapeutic goals in the treatment of Gaucher dis-
ease, Semin. Hematol. 41 (2004) 4–14.
[8] N.J. Weinreb, J. Charrow, H.C. Andersson, P. Kaplan, E.H. Kolodny, P. Mistry, G.
Pastores, B.E. Rosenbloom, C.R. Scott, R.S. Wappner, A. Zimran, Effectiveness of en-
zyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2
to 5 years of treatment: a report from the Gaucher registry, Am. J. Med. 113
(2002) 112–119.
[9] D. Elstein, G.M. Cohn, N. Wang, M. Djordjevic, C. Brutaru, A. Zimran, Early achieve-
ment and maintenance of the therapeutic goals using velaglucerase alfa in type 1
Gaucher disease, Blood Cells Mol. Dis. 46 (2011) 119–123.
[10] A. Zimran, N. Wang, C. Ogg, E. Crombez, G.M. Cohn, D. Elstein, Seven-year safety and
efﬁcacy with velaglucerase alfa for treatment-naïve adult patients with type 1
Gaucher disease, Am. J. Hematol. 90 (2015) 577–583.
[11] D.A. Hughes, D.E. Gonzalez, E.A. Lukina, A. Mehta, M. Kabra, D. Elstein, I. Kisinovsky,
P. Giraldo, A. Bavdekar, T.N. Hangartner, N. Wang, E. Crombez, A. Zimran,
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher
disease: long-term data from phase III clinical trials, Am. J. Hematol. 90 (2015)
584–591.
[12] H. Ben Turkia, D.E. Gonzalez, N.W. Barton, A. Zimran, M. Kabra, E.A. Lukina, P.
Giraldo, I. Kisinovsky, A. Bavdekar, M.F. Ben Dridi, N. Gupta, P.S. Kishnani, E.K.
Sureshkumar, N. Wang, E. Crombez, K. Bhirangi, A. Mehta, Velaglucerase alfa en-
zyme replacement therapy compared with imiglucerase in patients with Gaucher
disease, Am. J. Hematol. 88 (2013) 179–184.), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
7A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxx[13] D.E. Gonzalez, H. Ben Turkia, E.A. Lukina, I. Kisinovsky, M.F. Dridi, D. Elstein, D.
Zahrieh, E. Crombez, K. Bhirangi, N.W. Barton, A. Zimran, Enzyme replacement ther-
apy with velaglucerase alfa in Gaucher disease: results from a randomized, double-
blind, multinational, phase 3 study, Am. J. Hematol. 88 (2013) 166–171.
[14] L. Smith, W. Rhead, J. Charrow, S.P. Shankar, A. Bavdekar, N. Longo, R. Mardach, P.
Harmatz, T. Hangartner, H.M. Lee, E. Crombez, G.M. Pastores, Long-term
velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to en-
zyme replacement therapy or previously treated with imiglucerase, Mol. Genet.
Metab. 117 (2016) 164–171.
[15] N.J. Weinreb, J. Goldblatt, J. Villalobos, J. Charrow, J.A. Cole, M. Kerstenetzky, S.v.
Dahl, C. Hollak, Long-term clinical outcomes in type 1 Gaucher disease following
10 years of imiglucerase treatment, J. Inherit. Metab. Dis. 36 (2013) 543–553.
[16] WHO Study Group, Assessment of fracture risk and its application to screening for
postmenopausal osteoporosis. Report of a WHO study group, World Health Organ.
Tech. Rep. Ser. 843 (1994) 1–129.
[17] N. Weinreb, J. Taylor, T. Cox, J. Yee, S.v. Dahl, A benchmark analysis of the achieve-
ment of therapeutic goals for type 1 Gaucher disease patients treatedwith imigluce-
rase, Am. J. Hematol. 83 (2008) 890–895.
[18] E. Lukina, N. Watman, M. Dragosky, G.M. Pastores, E.A. Arreguin, H. Rosenbaum, A.
Zimran, J. Angell, L. Ross, A.C. Puga, J.M. Peterschmitt, Eliglustat, an investigational
oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treat-
ment, Blood Cells Mol. Dis. 53 (2014) 274–276.
[19] I. Tukan, I. Hadas-Halpern, G. Altarescu, A. Abrahamov, D. Elstein, A. Zimran,
Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease:
a single-center experience, Adv. Hematol. 2013 (2013) 151506.Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016[20] G.A. Grabowski, K. Kacena, J.A. Cole, C.E. Hollak, L. Zhang, J. Yee, P.K. Mistry, A.
Zimran, J. Charrow, S.v. Dahl, Dose-response relationships for enzyme replacement
therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1,
Genet. Med. 11 (2009) 92–100.
[21] P. Stein, A. Malhotra, A. Haims, G.M. Pastores, P.K. Mistry, Focal splenic lesions in
type I Gaucher disease are associated with poor platelet and splenic response to
macrophage-targeted enzyme replacement therapy, J. Inherit. Metab. Dis. 33
(2010) 769–774.
[22] A. Khan, T. Hangartner, N.J. Weinreb, J.S. Taylor, P.K. Mistry, Risk factors for fractures
and avascular osteonecrosis in type 1 Gaucher disease: a study from the Internation-
al Collaborative Gaucher Group (ICGG) Gaucher registry, J. Bone Miner. Res. 27
(2012) 1839–1848.
[23] C.E. Hollak, N. Belmatoug, J.A. Cole, S. Vom Dahl, P.B. Deegan, J. Goldblatt, B.
Rosenbloom, L. van Dussen, A. Tylki-Szymanska, N.J. Weinreb, A. Zimran, M.D.
Cappellini, Characteristics of type I Gaucher disease associated with persistent
thrombocytopenia after treatment with imiglucerase for 4–5 years, Br. J. Haematol.
158 (2012) 528–538.
[24] N.J. Weinreb, B.E. Rosenbloom, Splenomegaly, hypersplenism, and hereditary disor-
ders with splenomegaly, Open J. Genet. 3 (2013) 24–43.
[25] N.J. Weinreb, D.N. Finegold, E. Feingold, Z. Zeng, B.E. Rosenbloom, S.P. Shankar, D.
Amato, Evaluation of disease burden and response to treatment in adults with
type 1 Gaucher disease using a validated disease severity scoring system (DS3),
Orphanet J. Rare Dis. 10 (2015) 64.), http://dx.doi.org/10.1016/j.bcmd.2016.10.007
